Skip to content

Efficacy of Hybrid Systems (Topping Off) Versus Rigid Spinal Fusion in Lumbar Fusion Surgery: A Dual-center, Prospective, Randomized Pilot Study (CD Horizon BalanC)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02551302
Acronym
BalanC
Enrollment
60
Registered
2015-09-16
Start date
2015-10-31
Completion date
2017-12-31
Last updated
2015-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spine Surgery

Brief summary

Effectiveness of hybrid systems (topping off) compared to rigid spondylodesis in fusion surgery of the lumbar spine: A prospective, randomized, bicentric pilot study (CD HORIZON BalanC™)

Detailed description

Posterior spondylodesis and monosegmental intervertebral cage plus flexible spondylodesis of the superiorly adjacent segment (CD HORIZON BalanC™ Manufacturer: Medtronic) Control: Posterior spondylodesis and monosegmental intervertebral cage

Interventions

DEVICESolera™ Medtronic

The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic

DEVICECD HORIZON BalanC™ Medtronic

The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices: CD HORIZON BalanC™ Medtronic

Sponsors

Medtronic
CollaboratorINDUSTRY
University of Cologne
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent * Legal capacity * Age ≥ 30 years * Indication for monosegmental lumbar spine fusion (PLIF or topping-off ) L2-S1 with osteochondrosis Modic grades I-III \[20\]\[21\]\[22\] or spondylolisthesis Meyerding grades I-III. * Radiologic signs of degeneration in the adjacent segment of the intended fusion without signs of instability

Exclusion criteria

* Motor deficit * Cauda equina syndrome * Previous surgical intervention of the lumbar spine * Relevant peripheral neuropathy * Acute denervation subsequent to a radiculopathy * Scoliosis with Cobb angle greater than 25° * Spondylolisthesis \> Meyerding grade III * Radiologic signs of degeneration in the adjacent segment of the intended fusion with signs of instability (for definition, see inclusion criteria) * No radiologic signs of degeneration in the adjacent segment of the intended fusion (for definition, see inclusion criteria) * Radiologic signs of degeneration in the adjacent segment of the intended fusion with \>Fujiwara grade II \[15\] or \>Pfirrmann grade IV \[14\] * Signs of instability in any lumbar spine segment other than that undergoing fusion * General contraindication for elective lumbar spine surgery * Pathologic fracture * Osteoporosis with pathologic fracture * Active systemic infection * Rheumatic disease * Disease of bone metabolism (e.g. Paget's Disease) * Bone metastasis * Local infection focus lumbar spine * Seizure disorder * Chronic ischemia Fontaine classification IIb-IV * Severe heart insufficiency (NYHA III-IV) * Blood coagulation disorder or blood thinning therapy * Cortisone intake more than one month in the last 12 months before randomization * Simultaneous participation in another clinical trial in the 30 days before randomization * Known allergy or intolerance to the implants * Dependency on investigator * Lack of familiarity with the German language * Placement in an institution by governmental or juridical advice * Absent legal capacity * Pregnancy

Design outcomes

Primary

MeasureTime frame
Changes in the subscores of physical pain and physical function in the ODI QuestionaireBaseline to 6 month

Secondary

MeasureTime frame
MCS and individual dimensions and subscales of the SF-36™60 Month

Contacts

Primary ContactJan Siewe, Dr.med.
jan.siewe@uk-koeln.de+49(0)221-478-87294
Backup ContactMargarete Wicharz
margarete.wicharz@uk-koeln.de+49(0)221-478-87294

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026